Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of September 2016. The report discloses a corporate governance update regarding the appointment of a new member to the Scientific Advisory Board.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel appointment and associated compensation terms.
Material Changes
On September 7, 2016, the Board of Directors appointed Professor Shai Ashkenazi to the Scientific Advisory Board. The material change involves the following compensation structure:
- Consulting Fee: US$1,000 per day (or part thereof) for services rendered.
- Expense Reimbursement: Full reimbursement for out-of-pocket expenses.
- Equity Grant: Unregistered options for up to 54,000 ordinary shares (representing 1,350 ADSs).
- Exercise Price: $0.12 per share.
- Vesting Schedule: Four equal installments of 13,500 shares, commencing on the first anniversary of the appointment and continuing annually until fully vested at the fourth anniversary.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies are disclosed in this document, other than the standard terms of the option plan which requires approval at the upcoming annual general shareholders meeting.
Investor Verification Checklist
- Verify the approval status of the Company's option plan at the upcoming annual general shareholders meeting.
- Confirm the total number of shares outstanding to assess the dilution impact of the 54,000 new options.
- Review the terms of compensation for previous Scientific Advisory Board members to confirm consistency.
- Check for any subsequent filings regarding the actual utilization of consulting days by Professor Ashkenazi.